{"prompt": "['Date: June 30, 2020', 'Version: 8.0', 'Page: 23 of 52', 'procedure will continue for the testing of the secondary endpoints until statistical significance is not', 'achieved for a secondary endpoint.', 'Due to the COVID-19 pandemic, study enrollment was temporarily stopped, at which time a total of', '53 patients had been randomized to study drug treatment groups. 49 of these patients have', 'completed the study and 4 have withdrawn or early terminated. A futility interim analysis will be', 'conducted based on the data from these 53 patients. A recommendation to stop enrollment of the', 'study will be made by the unblinded statistician(s) if, for both dose groups, the conditional power is', 'less than 20% based on the primary endpoint AND the difference of the overall 12-week responder', 'rates is less than 2%. The interim analysis will be conducted by a group of people that are not', 'involved in the daily activities of the study. Details will be included in the SAP.', '6.7', 'Safety analyses', 'All AEs, whether considered drug-related or not, will be reported with a diagnosis, start/stop dates,', 'action taken, whether treatment was discontinued, any corrective measures taken, outcome, and', 'other possible causes. For all events, the relationship to treatment and the intensity of the event', 'will be determined by the investigator.', 'All AEs will be analyzed in terms of descriptive statistics and qualitative analysis. Treatment', 'emergent adverse events will be listed for each patient and summarized by system organ class (SOC)', 'and preferred term (PT) using the Medical Dictionary for Regulatory Activities (MedDRA).', 'Safety laboratory data, ECGs, physical examination findings, and vital signs measurements will be', 'listed for each patient and presented descriptively by treatment group and time point.', 'Safety variables may include but not limited to the following: laboratory changes (complete blood', 'counts, electrolytes, chemistry, and coagulation), changes in vital signs (blood pressure, heart rate,', 'respiratory rate, and temperature), and ECG and, in some instances, as produced at the', \"investigator's discretion.\", '6.8', 'Determination of sample size', 'The sample size calculation is based on the following assumptions: the weekly CSBM change from', 'baseline is 0.5 for the placebo group, and 1.5 for each active group, with common standard', 'deviation of 1.5; 50 patients in each group will have 90% power for each SYN-010 group compared', 'with the placebo by using the t-test with alpha=0.05.', '7. Study population', '7.1', 'Study population and statistical assumptions', 'A total of 150 adult IBS-C patients will be enrolled in a single site: 50 in the Placebo group and 50 in', 'each of the SYN-010 21 mg and SYN-010 42 mg treatment groups. The sample size calculation is', 'based on the t-test to achieve 90% power for each SYN-010 group when compared with the placebo', 'group.']['Date: June 30, 2020', 'Version: 8.0', 'Page: 24 of 52', '7.2', 'Eligibility criteria', 'Patients must meet all of the following inclusion and exclusion criteria to be included in the study.', '7.2.1', 'Inclusion criteria', '1.', 'Male or female participants aged between 18 and 65 years inclusive.', '2. Patient must be willing and able to participate in the study for the required duration,', 'understand and sign the informed consent form (ICF), and be willing to comply with all', 'protocol-related visits and procedures.', '3. Patient has had IBS-C symptoms (as defined by Rome IV diagnostic criteria) for at least 6', 'months prior to diagnosis.', '4.', 'Patient has an average score of 3.0 for daily abdominal pain at its worst (11-point numerical', 'rating scale [NRS]) during and up to the 17 days immediately before randomization (i.e. Pre-', 'treatment Period).', '5.', 'Patient has an average of < 3 CSBMs per week or < 5 SBMs per week during the 17 days', 'immediately before randomization (i.e. Pre-treatment Period).', '6.', 'Patient has a breath methane level 10 ppm on a lactulose breath test administered at', 'Screening.', '7. Patient may be on a stable, continuous regimen of fiber or probiotics one month before the', 'Screening Visit; however, they must maintain a stable dose regimen through Week 12.', '8. Patient must agree to refrain from starting a new diet, changing stable dose of supplemental', 'fiber, or changing exercise pattern that may affect IBS-C symptoms from the time of', 'Screening through the end of the study. If the patient takes food products that are strong', \"inhibitors of cytochrome P450 3A (CYP3A) (e.g. grapefruit juice, Seville orange juice, St. John's\", 'Wort), he/she must agree to refrain from taking these from the time of Screening through', 'the end of the study.', '9. Patient must agree to use an acceptable method of contraception from the time of signing', 'the ICF to 30 days after the final dose of study drug if the patient is a sexually active female of', 'child-bearing potential (defined as any female who has experienced menarche and who is', 'NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive', 'months with no menses without an alternative medical cause). Adequate contraceptive', 'measures include: oral contraceptives (stable use for two or more cycles before Screening);', 'intrauterine device; Depo-Provera\u00ae; Norplant System implants; partner with a vasectomy;', 'double-barrier birth control (e.g. use of a condom plus diaphragm or condom plus either', 'contraceptive sponge, foam, or jelly); or abstinence. According to drug research standards,', 'male patient must agree to use an acceptable method of contraception and refrain from', 'donating sperm from the time of signing the ICF to 90 days after the final dose of study drug.', '10. A female patient of child-bearing potential must be non-pregnant and non-lactating and have', 'negative pregnancy tests at the Screening Visit and on Day 1 prior to dosing with study drug.', '11. Patients must be able to understand and be willing to sign the written informed consent', 'form. A signed informed consent form must be appropriately obtained prior to the conduct', 'of any trial-specific procedure.', '12. Willing and able to comply with the protocol, including follow-up visits and examinations.']\n\n###\n\n", "completion": "END"}